



Microbial Warfare in the Gut: Unveiling the Battle between Enterotoxigenic *Bacteroides Fragilis* and Bacteriophages

Longzhu Cui*, Mahmoud Arbaah, Nguyen Minh Thuy, Yoshifumi Aiba and Shinya Watanabe

Department of Infection and Immunity, Jichi Medical University, Japan

*Corresponding author: Longzhu Cui, Division of Bacteriology, Department of Infection and Immunity, Jichi Medical University, Tochigi, Japan.

Received Date: November 09, 2023

Published Date: November 17, 2023

Introduction

This review delves into the microbial battleground of the human gut, unraveling the conflict between Enterotoxigenic *Bacteroides fragilis* (ETBF) and bacteriophages. ETBF, a potential contributor to colorectal cancer, faces opposition from bacteriophages, offering therapeutic promise. This exploration underscores the significance of understanding gut microbial dynamics for innovative health interventions.

Text

Enterotoxigenic *Bacteroides fragilis* (ETBF) is a specific strain of the bacterium *Bacteroides fragilis* that has garnered significant attention due to its association with various human diseases. Unlike its non-enterotoxigenic counterparts, ETBF possesses the ability to produce a heat-labile enterotoxin known as B. fragilis toxin (BFT) [1]. This toxin has been implicated in promoting inflammation, disrupting the intestinal barrier, and potentially contributing to the development of colorectal cancer [1]. The association between ETBF and colorectal cancer highlights the intricate interplay between gut microbiota and human health [2]. It is intriguing to explore how a seemingly harmless bacterium can transform into a potential threat through the acquisition of specific virulence factors. The implications for understanding and managing gastrointestinal diseases, particularly colorectal cancer, make ETBF a subject of significant scientific interest [2]. Moreover, exploring the role of ETBF in the context of dysbiosis and its impact on the overall gut microbiome provides valuable insights into the complex ecosystem within our digestive system [2]. As we continue to unravel the

mysteries of the gut microbiota, ETBF stands out as a key player in the intricate web of microorganisms that influence our health [2]. On the other side of the microbial battlefield, we have bacteriophages—nature's own bacterial predators. Bacteriophages, or simply phages, are viruses that infect and replicate within bacteria. They are the most abundant entities on Earth, outnumbering bacteria in most environments, and play a crucial role in shaping microbial communities [3]. The potential of bacteriophages as therapeutic agents against bacterial infections, including those caused by ETBF, is an exciting avenue of research [4]. Harnessing the specificity of phages to target particular bacterial strains, such as ETBF, could provide a highly targeted and potentially more precise alternative to traditional antibiotics [4]. This is particularly appealing given the rising concerns about antibiotic resistance. The application of phage therapy in the context of ETBF could involve designing phages that specifically target and neutralize the pathogenic strains, offering a more tailored approach to treatment [4]. Furthermore, exploring the interactions between phages and ETBF in the complex environment of the gut microbiome adds another layer of complexity to this microbial drama.

Bacteriophages, beyond their potential therapeutic role, contribute significantly to the biodiversity of microbial communities. Recent research by Suttle (2007) emphasizes the impact of phages as major drivers of microbial evolution and diversity. Their ability to modulate bacterial populations and shape community dynamics highlights the intricate relationship between phages and their bacterial hosts [5]. In the microbial battleground of

the human gut, the dynamic relationship between Enterotoxigenic *Bacteroides fragilis* and bacteriophages unfolds as a captivating story. ETBF, armed with its enterotoxin, poses a potential threat to gut health and has been implicated in colorectal cancer. On the other front, bacteriophages emerge as promising warriors and/or genetic crusaders [6], ready to selectively target and eliminate specific bacterial foes. In the complex gut microbial battleground, the clash unfolds between Enterotoxigenic *Bacteroides fragilis* (ETBF) and bacteriophages. ETBF, linked to colorectal cancer, confronts bacteriophages, signaling therapeutic potential. The intricate interplay emphasizes the need to fathom gut microbial dynamics for innovative health interventions. Bacteriophages emerge as promising warriors, countering the impact of ETBF and paving the way for targeted therapies. As the microbial drama plays out, nature's solutions emerge, holding the key to maintaining a balanced and healthy gut microbiome.

Funding

This work was supported by the Japan Agency for Medical Research and Development (Grant No. JP22ae0121045, JP21gm1610002 and JP22fk0108532 to LC), and Cabinet Office, Government of Japan (Grant No. JPJ009237 to LC).

Acknowledgement

None.

Conflict of Interest

No Conflict of interest.

References

1. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat Med* 15(9): 1016-1022.
2. Sears CL, Garrett WS (2014) Microbes, microbiota and Colon Cancer. *Cell Host Microbe* 15(3): 317-328.
3. Al-Shayeb B, Sachdeva R, Chen LX, Ward F, Munk P, et al. (2020) Clades of huge phages from across Earth's ecosystems. *Nature* 578(7795): 425-431.
4. Shen J, Zhang J, Mo L, Li Y, Li Y, et al. (2023) Large-scale phage cultivation for commensal human gut bacteria. *Cell Host and Microbe* 31(4): 665-677.
5. Suttle CA (2007) Marine viruses--major players in the global ecosystem. *Nature Reviews Microbiology* 5(10): 801-812.
6. Cui L, Veerananarayanan S, Thitianapakorn K, Wannigama DL (2023) Bacteriophage Bioengineering: A Transformative Approach for Targeted Drug Discovery and Beyond. *Pathogens* 12(9): 1179.